Objective: The incidence of Ewing sarcoma is lower in non-Caucasian populations, compared with Caucasian populations, for unknown reasons. Most studies from western countries have reported improvement in outcomes following multi-agent chemotherapy, with no difference in outcome between skeletal and extraskeletal Ewing sarcoma. However, there are few studies of Ewing sarcoma in non-Caucasian populations, with especially few comparing outcomes between skeletal and extraskeletal Ewing sarcoma. Thus, the purpose of this study is to determine whether the outcomes and prognostic factors of Ewing sarcoma in the Japanese population are similar to those in Caucasian populations and to determine whether skeletal and extraskeletal Ewing sarcoma have similar outcomes in Japanese patients. Methods: We retrospectively evaluated the outcomes of 74 Japanese patients with Ewing sarcoma treated between 1981 and 2011 from the Osaka University Orthopaedic Oncology Group. Results: Extraskeletal Ewing sarcoma, tumors in the extremities, localized disease at presentation and diagnosis after 2000 were significantly associated with a favorable outcome. Among patients with localized disease at presentation, a significantly better outcome was observed for those with extraskeletal Ewing sarcoma, those who underwent a VDC/IE based or VAIA chemotherapy protocol, and those who were diagnosed after 2000. In the multivariable analyses, extraskeletal Ewing sarcoma was an independent predictor of increased overall survival among all patients and the subset of patients with localized disease. Conclusions: The outcome of patients with Ewing sarcoma in Japan has improved in the last decade. The outcomes and prognostic factors are similar for Japanese and Caucasian patients, though in this series of Japanese patients, a better prognosis was observed for patients with extraskeletal rather than skeletal Ewing sarcoma.
Introduction
The Ewing sarcoma family of tumors (ESFT) represents the second most frequent bone malignancies in children. The ESFT is a family of morphologically similar malignancies that includes classic Ewing tumors, atypical Ewing tumors, Askin tumors of the chest and peripheral primitive neuroectodermal tumors. These tumors can arise from bone (skeletal) or soft tissue (extraskeletal).
ESFT are found much more frequently in Caucasian populations than African or Asian populations (1) . According to the Surveillance, Epidemiology and End Results (SEER) data in the USA, 92% of ESFT cases were diagnosed in individuals of Caucasian descent (2) . While 200 new ESFT cases are reported annually to the SEER in the USA (2) , only approximately 50 new cases are registered in Japan in the Bone and Soft Tissue Tumor Registry, which is maintained by the Japanese Orthopaedic Association Musculoskeletal Tumor Committee, despite the fact that the US population is approximately 2.5 times that of the Japanese population. The population-adjusted incidence of ESFT in Caucasians is 9-fold higher than in African-Americans and 2.5-fold higher than in Asian-Americans (2) . The reasons for these racial differences in the incidence of ESFT are unclear.
Over the past several decades, improvements in outcomes for patients with skeletal Ewing sarcoma (SES) have been achieved through multidisciplinary approaches and multi-institutional trials conducted in Europe and North America (3) (4) (5) (6) . Several studies have reported prognostic factors for SES, such as the patient's age, tumor location, tumor volume, metastasis at presentation, response to chemotherapy, serum lactate dehydrogenase level and EWS-FLI1 fusion type (3, (7) (8) (9) .
On the other hand, extraskeletal Ewing sarcoma (EES) is rare, and historically it has been treated with a rhabdomyosarcoma protocol (10) . Therefore, its clinical features, treatment characteristics and prognostic factors have been difficult to establish. Some small studies comparing the outcomes of EES and SES in Caucasian patients indicated that the two groups of patients had similar outcomes (11) . However, few studies have investigated the prognostic factors of EES in non-Caucasian patients. Therefore, the prognostic difference between EES and SES in non-Caucasian patients is unknown. The purpose of this study is to assess the prognosis of ESFT in Japanese patients by evaluating the outcomes of our cases and to elucidate the prognostic differences between EES and SES in Japan.
Patients and methods
We retrospectively reviewed 74 patients with ESFT treated from 1981 to December 2011 in one of four tertiary referral hospitals affiliated with the Osaka University Orthopaedic Oncology Group (Osaka University Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka National Hospital and Himeji Red Cross Hospital). The diagnosis of ESFT was based on standard histopathological criteria and was confirmed by the detection of EWS-FLI1 or EWS-ERG using reverse transcriptase-polymerase chain reaction (RT-PCR) in cases after 2004.
All patients underwent chemotherapy. Surgical resection was performed if the surgeon judged that complete resection was possible. Patients with an obscure surgical margin in the primary site were treated with post-operative radiotherapy. Patients with lesions determined to be non-resectable with a secure margin received radiotherapy. If after radiation the tumor was deemed resectable with acceptable morbidity, it was surgically resected.
We collected patient data from their medical records, including sex, age at diagnosis, primary type (SES or EES), primary location (extremity or trunk), tumor size, disease stage at presentation, local treatment, initial chemotherapy protocol, surgical margin and year of diagnosis.
For the statistical analyses, the above variables were considered potential prognostic factors. The correlations between these factors were analyzed using Fisher's exact test. Overall survival (OS) was calculated from the initiation of treatment and estimated by Kaplan-Meier methods. Overall survival curves were compared using a Wilcoxon analysis for univariate survival analysis. Multivariate analysis was performed using Cox's proportional hazards model (JMP Pro version 11.2.1, SAS Institute, Cary, NC).
Results

Demographics
The clinical characteristics of the patients are listed in Table 1 . Of the 74 patients, 49 (66.2%) had SES and 25 (33.8%) had EES. The diagnosis of ESFT was confirmed by the detection of EWS-FLI1 using RT-PCR for 10 SES and 4 EES cases. There were 34 men (45.9%) and 40 women (54.1%). The median age at diagnosis was 17 years old (range: 1-64 years). Thirty patients had extremity-based tumors, including those on the lower (n = 18) and upper (n = 12) extremities. Fortyfour patients had trunk-based tumors, including those on the pelvic girdle and girdles of the lower extremities (n = 14), abdominal and thoracic wall (n = 14), spine and para-spinal area (n = 8), girdles of the upper extremities (n = 5) and head and neck (n = 3). The data describing the maximal tumor size were available in 63 cases. Tumor size was categorized as <5 cm (n = 12), between 5 and 10 cm (n = 30), and >10 cm (n = 21). Fifty-eight patients had localized disease and 16 patients had metastasis at presentation, including lung (n = 9), bone (n = 6) and lymph node (n = 1) metastasis. Of the 44 patients with trunk ESFT, 14 (31.8%) had metastasis at presentation, while two of 30 (6.7%) patients with ESFT in the extremities had metastasis at presentation (P = 0.010). Thirty-six patients (48.6%) were diagnosed between 1981 and 1999, and 38 patients (51.4%) were diagnosed between 2000 and 2011.
The initial chemotherapy protocols used varied by treatment period and included VDC/IE (n = 31), VDC/IFO (n = 10), VDC/ICE (n = 5), VAIA (n = 3), T11 (n = 18) and others (DXR or CDDP-based regimens; n = 7). Thirty-four of the 38 patients diagnosed from 2000 to 2011 underwent a VDC/IE, VDC/IFO, VDC/ICE or VAIA protocol. As local treatment, 40 patients were treated with surgery alone, 22 with both surgery and radiotherapy (5 patients received preoperative radiotherapy) and 12 with radiation alone. Forty-eight patients underwent surgical resection with a wide margin, 6 patients with a marginal margin and 8 patients with an intralesional margin. Thirteen of 14 patients with a marginal or intra-lesional margin underwent radiotherapy. The median follow-up period was 44 months (range: 8-248 months).
Characteristic differences between EES and SES
The mean age of patients with EES was significantly higher than that of patients with SES (P < 0.001), and there was a tendency toward a higher proportion of patients with EES after 2000 compared with before 1999 (P = 0.051). There were no differences in sex, tumor location, tumor size, local treatment modality, chemotherapy protocol, surgical margin or presence of metastasis at presentation between the EES and SES groups.
Patient outcomes
The 5 year OS was superior for patients diagnosed after 2000 compared with those diagnosed before 1999 in the total sample (78.0 vs. 46.0%, P = 0.008, Fig. 1 ); this remained significant among patients with localized tumors (83.4 vs. 57.6%, P = 0.035) and patients with metastatic disease (56.3 vs. 0.0%, P = 0.019) ( Table 2) .
In all patients, the 5-year OS was significantly better for patients with EES than SES (83.1 vs. 49.0%, P = 0.015, Fig. 2 ). Extremity tumors (P = 0.005) and an absence of metastasis at presentation (P < 0.001, Fig. 3 ) were significant predictors of a favorable OS (Table 2) . Gender, age, tumor size, chemotherapy protocol, local treatment method and surgical margin were not significant predictors of OS in the analyses of all patients. In the multivariable analysis, EES was an independent predictor of better OS, as was an absence of metastasis at diagnosis, location in the extremities and diagnosis after 2000 (Table 3) .
Among patients with localized disease at presentation, the OS was superior for patients with EES compared with those with SES (P = 0.017, Fig. 4) , and patients who received a VDC/IE based or VAIA chemotherapy protocol had a better prognosis for OS (P = 0.037, Fig. 5 ) than patients who received chemotherapy under other protocols (Table 2) . We did not find a significant impact of gender, age, tumor location, tumor size, local treatment method or surgical margin on OS for patients with localized tumors. In the multivariable analysis, EES was the only independent predictor of improved OS in patients with localized tumors (Table 3) .
Among patients with metastatic disease at presentation, OS did not differ between EES and SES, but the site of metastasis was a prognostic factor for OS. Patients with bone metastasis at presentation had a poorer prognosis than patients with lung or lymph node metastasis (P = 0.009, Fig. 6 ).
Discussion
We explored the characteristics differences between EES and SES and assessed the prognosis of Japanese patients with ESFT by evaluating the outcomes of our series of cases. Our results demonstrated that clinical outcome improved for patients diagnosed after the year 2000, and outcomes became similar to those of ESFT patients in western countries. We also found that patients with localized tumors, tumors in the extremities and EES had an improved prognosis compared with their counterparts. Our study revealed that the mean age of patients with EES was significantly higher than that of patients with SES. This age distribution difference between SES and EES is also reported in the SEER analysis (2) . This difference in the age distribution between EES and SES suggests that they may have subtle biological differences. We also found that a larger percentage of the patients with EES were diagnosed after 2000. Seventeen of 25 patients with EES (68%) were diagnosed after 2000, while 21 of 49 patients (42%) with SES were diagnosed after 2000, though this is not statistically significant (P = 0.051). This increase in the EES population was also shown in other reports (2) . It likely reflects the more recent recognition and reporting of EES as opposed to a true increase in its incidence.
Many prior studies from western countries have suggested that outcomes are similar for patients with EES and SES (11, 12, 15) . Two prospective studies also found similar outcomes for EES treated with SES protocols (13, 14) . In contrast, we found that patients with EES had a more favorable outcome than those with SES (5-year estimate of 89.7% for localized EES vs. 58.3% for localized SES, P = 0.019). Our results are congruent with two more recently published large studies, which included many non-Caucasian ESFT patients. Biswas et al. (12) reported that in India, patients with EES had a significantly higher event free survival rate compared with those with SES (5-year estimate of 62% for EES vs. 31.7% for SES, P = 0.01) in their study of 374 localized ESFT patients treated with a uniform chemotherapy protocol (VDC/IE). Applebaum et al. (2) also reported using data from the SEER program (n = 2202; including 9.9% non-Caucasian) that the rate of OS was significantly superior for patients with EES compared with patients with SES among localized patients (5-year estimate of 69.7% for EES vs. 62.6% for SES, P = 0.02). These results suggest the possibility that racial differences may impact the outcome of EES and SES. The impact of race on clinical outcome of ESFT was investigated by Jawad et al. (13) . In their study, survival was not impacted by race, and they did not find prognostic differences between EES and SES in the subset of non-Caucasian patients. However in their study, the small number of non-Caucasian patients in each category limited the statistical power for analysis. The impact of racial differences on the outcome of ESFT cannot be ruled out. Several studies reported the prognostic factors of ESFT, including the patient's age, tumor location, tumor volume, metastasis at presentation, serum lactate, response to chemotherapy, local therapy, surgical margin or fusion variant (3, (7) (8) (9) . Our results support the effect of tumor location, as patients with trunk tumors have a poorer prognosis than those with tumors of the extremities (7). This is partially because in our study more patients with ESFT in the trunk had metastasis at presentation compared with patients with ESFT in the extremities. In this series, 31.8% (14/44) of the patients with trunk ESFT had metastasis at presentation, while 6.7% (2/30) of the patients with extremity ESFT had metastasis at presentation (P = 0.010). We were not able to show a significant correlation between the survival rate and local treatment or surgical margin. However, we do not believe that it is acceptable to administer radiation only for local treatment or purposefully leave an inadequate surgical margin. In this study, we had too few patients treated with radiation alone (N = 12) to show significant differences in outcome. Some studies that included many cases revealed that local control rates or the overall survival rate for patients managed with radiation alone are poorer than those in patients undergoing surgery, and larger studies also show that the surgical margin has an impact on the outcome (14) (15) (16) (17) . Some authors reported the effectiveness of adjuvant radiotherapy for patients with an inadequate surgical margin or a poor response to chemotherapy (14, 18, 19) . In our study, 13 of 14 patients treated with an inadequate surgical margin underwent radiotherapy. The adjuvant radiotherapy was suspected to improve the outcome for the patients with an inadequate margin. We believe that surgical resection with a wide margin should be performed for all patients with resectable tumors, and adjuvant radiotherapy should be added for patients with an inadequate surgical margin or a poor response to chemotherapy.
Our data indicate that clinical outcomes after treatment for ESFT have improved since 2000. Outcomes in Japanese patients have become comparable to those seen in western countries. One reason for this improvement is chemotherapeutic progress. Thirty-four of 38 patients (89.5%) diagnosed after 2000 were treated with a VDC/IEbased or VAIA protocol in this study, while 15 of 36 patients (41.7%) diagnosed before 1999 were treated with these protocols. Use of a VDC/IE or VAIA protocol is now considered the standard chemotherapy protocol for ESFT patients. We observed a prognostic benefit of a VDC/IE-based or VAIA protocol, compared with other protocols, in patients with localized disease (Table 2) . Our results confirm the efficacy of these protocols for treating ESFT patients in Japan, as previously reported (20) . However, the chemotherapy protocol used did not significantly affect the outcome of patients with metastatic tumors in this study. The presence of metastatic disease is recognized in multiple studies as the most detrimental factor to ESFT prognosis, with an estimated survival of ∼25% at 5 years (21), which is similar to our results. Treatment of metastatic ESFT patients is challenging. The value of high-dose chemotherapy (HDC) followed by hematopoietic cell transplantation (HCT) in the treatment of high-risk metastatic ESFT patients has not been established (22) . Some studies have found that whole-lung radiation therapy for patients with lung metastasis from ESFT is effective (22) . Establishing a standard treatment for metastatic ESFT patients remains a major issue.
This study has some limitations. The first limitation is the small sample size due to the rarity of this disease in Asian populations. Second, this study included patients treated over a long span of time. Therefore, several different chemotherapy protocols were used. However, the groups of patients that received a VDC/IE-based or VAIA chemotherapy protocol, which are now considered the first line protocols in ESFT treatment, were similar between those with EES and SES. Third, we were not able to obtain information describing the response to chemotherapy or dose intensity of chemotherapy, which may affect the outcome. Many previous articles demonstrated that the response to preoperative chemotherapy was significantly correlated with the prognosis of ESFT (7, 14, 23) . Two randomized controlled trials examining dose intensity reported that chemotherapy intensification through interval compression of VDC/IE improved the outcome of ESFT (24) , while no improvement in outcome was observed after increasing the administered dose (25) .
In 2004, the Japan Ewing Sarcoma Study Group (JESS), which is composed of specialists in multiple fields, such as orthopedic surgeons, pediatric oncologists, radiation oncologists and pathologists, was organized to improve the treatment results of Japanese patients with Ewing sarcoma. We believe that this multidisciplinary approach contributes to the improvement in outcomes in this study and makes aggressive treatments possible, such as HDC followed by HCT or whole-lung radiotherapy. Furthermore, this group is conducting a prospective study for ESFT that includes EES and SES. This study will clarify whether the clinical outcome of EES is similar to SES in Asia. Additionally, the worldwide prospective study of ESFT will elucidate whether racial differences impact the outcome of EES and SES, and it may reveal other patient-related factors affecting outcome that can provide new strategies for the treatment of ESFT.
In conclusion, the current study indicates that the outcome and prognostic factors of Japanese patients with ESFT are similar to those of Caucasian patients, though Japanese patients with EES have a better prognosis than those with SES.
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